<div id="readability-page-1">10:29 AM EST, 12/01/2025 (MT Newswires) -- Lenz Therapeutics ( LENZ ) and Lotus Pharmaceutical said Monday that Lotus submitted a new drug application to South Korea's Ministry of Food and Drug Safety for Vizz to treat presbyopia in adults.The submission was supported by data from phase 3 trials in the US in which Vizz met all primary and secondary near vision improvement endpoints, the companies said.Under the May 2025 license and commercialization agreement, Lenz Therapeutics ( LENZ ) is eligible to receive up to $125 million in regulatory and commercial milestone payments along with tiered, double-digit royalties on future net sales, according to the companies.Shares of Lenz Therapeutics ( LENZ ) were down over 1% in recent trading.Price: 29.72, Change: -0.80, Percent Change: -2.63 MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

LENZ

Lenz Therapeutics and Lotus Pharmaceutical have submitted a new drug application for Vizz, a presbyopia treatment, to South Korea's Ministry of Food and Drug Safety. The application is backed by successful phase 3 trial data from the US. Lenz Therapeutics may receive up to $125 million in milestone payments and royalties. Lenz's shares fell over 1%, trading at $29.72.

Lenz Therapeutics, Lotus Pharmaceutical Say New Drug Application for Presbyopia Treatment Submitted in South Korea